STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [Form 3] Keros Therapeutics, Inc. Initial Statement of Beneficial Ownership

Director Anne Prener files Form 3 insider report at Keros Therapeutics (KROS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Keros Therapeutics, Inc. filed an insider ownership report on Form 3 for Anne Prener

Positive

  • None.

Negative

  • None.
Net buy/sell shares 0 shares netBuySellShares in Form 3 transaction summary
Reported share purchases 0 shares buyShares in Form 3 transaction summary
Reported share sales 0 shares sellShares in Form 3 transaction summary
Derivative exercises 0 shares exerciseShares in Form 3 transaction summary
Form 3 regulatory
"Insider ownership report on Form 3 for Keros Therapeutics, Inc."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
reporting person regulatory
"The filing identifies Anne Prener as a reporting person and director."
derivative transactions financial
"The summary shows no derivative transactions or remaining derivative positions."
Derivative transactions are contracts whose value depends on the price or performance of something else—like stocks, bonds, currencies, interest rates or commodities. Think of them as insurance or bets about a future price: investors use them to protect against losses, lock in prices, or try to amplify returns, but they can also magnify losses, create cash demands and expose a firm to the risk that the other party won’t meet its obligation, so they can materially affect a company’s financial stability and volatility.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does the KROS Form 3 filing for Anne Prener show?
The Form 3 for Keros Therapeutics, Inc. reports director Anne Prener as a reporting person. It does not list any share purchases, sales, gifts, or derivative exercises in this filing.

Did Anne Prener buy or sell Keros Therapeutics (KROS) shares in this Form 3?
No transactions are reported. The Form 3 for Keros Therapeutics, Inc. shows zero share purchases, sales, gifts, or exercises for director Anne Prener in this submission.

Is Anne Prener a director or officer of Keros Therapeutics (KROS)?
The Form 3 identifies Anne Prener as a director of Keros Therapeutics, Inc. She is not listed as an officer and is not reported as a ten percent owner in this filing.

Does the Keros Therapeutics (KROS) Form 3 include derivative securities?
The Form 3 summary shows no derivative transactions or remaining derivative positions for director Anne Prener. Derivative-related counts, including exercises, are all reported as zero in this filing.

What is the overall net share activity in the KROS Form 3 for Anne Prener?
The transaction summary shows netBuySellShares of 0 and a neutral net direction. This indicates no net buying, selling, or other share movements were reported in this Form 3 filing.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Prener Anne
(Last)(First)(Middle)
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2026		3. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Esther Cho, Attorney-in-Fact07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR